CClinicalTrials.gg
CompletedNCT02418871Updated May 21, 2021

Evaluation of the FluidVision Accommodating Intraocular Lens (AIOL) With an Improved Injector System

An interventional study of FluidVision AIOL and Cataract surgery in Aphakia, sponsored by PowerVision. Completed at 5 sites in 2 countries. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2021-05-21.

Sponsored by PowerVision · Not applicable, Interventional, and Device feasibility

Phase
Not applicable
Study type
Interventional
Enrollment
53
Allocation
Not applicable
Ages
50 Years and older
Sex
All
01

Study summary

The purpose of this study is to evaluate the clinical outcomes of an investigational IOL in patients undergoing cataract extraction and intraocular lens implantation using an improved injector system.

02

Conditions studied

  • Aphakia

Browse trials for

Keywords

  • Cataract
03

Who can participate

Ages eligible
50 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Eligible for primary intraocular lens implantation for the correction of aphakia following cataract extraction;
  • Best corrected distance visual acuity worse than 20/40 either with or without a glare source present (e.g. Brightness Acuity Tester);
  • Less than or equal to 1.0 diopter (D) of preoperative keratometric astigmatism;
  • Willing and able to comply with schedule for follow-up visits for 36 months after surgery.
  • Other protocol-defined inclusion criteria may apply.

Key Exclusion Criteria:

  • Systemic disease that could increase the operative risk or confound the outcome (e.g. autoimmune disease, diabetes);
  • Taking systemic medications that may confound the outcome or increase the risk to the subject;
  • Ocular conditions that may predispose for future complications;
  • Previous intraocular or corneal surgery that might confound the outcome of the investigation or increase the risk to the subject;
  • Pregnant, lactating during the course of the investigation, or with another condition associated with fluctuation of hormones that could lead to refractive changes;
  • Diagnosed degenerative visual disorders (e.g. macular degeneration or other retinal disorders) that are predicted to cause future best corrected visual acuity loss worse than 20/40.
  • Other protocol-defined exclusion criteria may apply.
04

Study design

Phase
Not applicable
Primary purpose
Device feasibility
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
53 participants (actual)

Study arms

  • Experimental
    FluidVision

    FluidVision AIOL implanted in the capsular bag of the eye during cataract surgery

    Device: FluidVision AIOL · Procedure: Cataract surgery

Interventions

  • DeviceFluidVision AIOL

    Investigational implantable medical device intended for long-term use over the lifetime of the cataract subject. An improved injector system was used.

  • ProcedureCataract surgery

    Performed using standard microsurgical techniques

05

What researchers measure

Primary outcomes

  1. Accommodative amplitude

    Accommodative amplitude is a measure of the ability of the eye to focus from a target that is at distance into a target that is near.

    Time frame: Month 6

  2. Best corrected distance visual acuity (BCDVA)

    Visual acuity of the eye will be tested with the correction in place.

    Time frame: Month 6

  3. Rates of adverse events

    Adverse events will be collected from time of enrollment to study exit.

    Time frame: Up to Month 36

06

Study locations

5 sites
  • PowerVision Investigative Site
    Budapest, Hungary
  • PowerVision Investigative Site
    Claremont, Cape Town 2001, South Africa
  • PowerVision Investigative Site
    Northcliff, Johannesburg 2001, South Africa
  • PowerVision Investigative Site
    Queenswood, Pretoria 2001, South Africa
  • PowerVision Investigative Site
    Somerset West, South Africa
07

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT02418871
Lead sponsor
PowerVision
Responsible party
Sponsor
First posted
Apr 16, 2015
Start date
Mar 13, 2015
Primary completion
Mar 16, 2016
Completion
Sep 5, 2018
Last update
May 21, 2021

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion